Please assess the completion status of the following clinical trial:

Trial Title: LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria :~1. Biopsy proven breast carcinoma which is persistent and metastatic or recurrent and metastatic.~2. Patients must have failed at least one line of chemotherapy for metastatic disease.~3. Patients who are Human epidermal growth factor 2 +(HER2+) as defined by American Society of Clinical Oncology and College of American Pathologists (ASCO CAP) guidelines must have failed all prior therapy known to confer clinical benefit~4. Patients must have at least 3 distinct metastatic sites with at least one measurable lesion which is at least 1 cm or larger in largest diameter~5. At the time of enrollment, patients must be ≥ 4 weeks since all of the following treatments (and recovered from the toxicity of prior treatment to \<= Grade 1, exclusive of alopecia):~   major surgery; radiotherapy; chemotherapy (note: must be ≥ 6 weeks since therapy if treated with a nitrosourea, mitomycin, or monoclonal antibodies such as bevacizumab); immunotherapy; Biotherapy/targeted therapies.~6. Patient ≥ 18 years of age. Patient life expectancy \> 6 months. Eastern cooperative group (ECOG) of 0 or 1~7. Adequate organ function including:~   1. Marrow: Hemoglobin \>= 10.0 g/dL, absolute neutrophil count (ANC) \>=1,500/mm3, and platelets \>=100,000/mm3.~  2. Hepatic: Serum total bilirubin \<=1.5 x upper limit of normal (ULN) (Patients with Gilbert's Disease may be included if their total bilirubin is \<= 3.0 mg/dL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \<= 2.5 x ULN. If the patient has known liver metastases, an ALT and/or AST \<= 5 x ULN are allowed.~  3. Renal: Estimated or measured creatinine clearance \>= 60 mL/min.~  4. Other: Prothrombin time (PT) and partial thromboplastin time (PTT) \< ULN.~8. Patients must have negative tests (antibody and/or antigen) for hepatitis viruses B and C unless the result is consistent with prior vaccination or prior infection with full recovery.~9. Male and female patients of child-producing potential must agree to use effective contraception while enrolled on study and receiving the experimental drug, and for at least 3 months after the last treatment.~Exclusion Criteria :~1. Patients diagnosed with another malignancy - unless following curative intent therapy, the patient has been disease free for at least 2 years and the probability of recurrence of the prior malignancy is \< 5%. Patients with curatively treated early-stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN) are eligible for this study.~2. Concurrent cancer therapy is not permitted.~3. Uncontrolled central nervous system (CNS) metastases, meningeal carcinomatosis, malignant seizures, or a disease that either causes or threatens neurologic compromise (e.g., unstable vertebral metastases).~4. History of ascites or pleural effusions, unless successfully treated.~5. Patients with an organ transplant, including those that have received an allogeneic bone marrow transplant.~6. Patients on immunosuppressive therapy including:~   1. Systemic corticosteroid therapy for any reason, including replacement therapy for hypoadrenalism. Patients receiving inhaled or topical corticosteroids may participate (if therapy is \< 5 days and is limited to systemic steroids as antiemetics).~  2. Patients receiving cyclosporine A, tacrolimus, or sirolimus are not eligible for this study.~7. Use of investigational agents within 4 weeks prior to study enrollment (within 6 weeks if the treatment was with a long-acting agent such as a monoclonal antibody).~8. Patients with moderate or severe cardiac disease:~   1. have the presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension.~  2. have documented major electrocardiogram (ECG) abnormalities (not responding to medical treatments) at the investigator's discretion (for example, symptomatic or sustained atrial or ventricular arrhythmias, second- or third-degree atrio ventricular block, complete bundle branch block, ventricular hypertrophy, or recent myocardial infarction).~  3. have major abnormalities documented by echocardiography (ECHO) with Doppler (for example, moderate or severe heart valve function defect and/or left ventricular ejection fraction \<50%, evaluation based on the institutional lower limit of normal). For additional details, refer to ECHO protocol.~  4. have predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress (for example, family history of aneurysms, Marfan-Syndrome, bicuspid aortic valve, evidence of damage to the large vessels of the heart documented by computed tomography (CT) scan with contrast).~9. B-type Natriuretic Peptide (BNP) above 3 times the baseline value and above the ULN that is sustained consecutive, scheduled blood draws. Troponin I above ULN, high sensitive C-reactive protein (hsCRP) above ULN or Cystatin above ULN.~10. Patients with a remote history of asthma or active mild asthma may participate.~11. Active infection, including unexplained fever (temperature \> 38.5 deg.C).~12. Systemic autoimmune disease (e.g., systemic lupus erythematosus, active rheumatoid arthritis, Marfan Syndrome, etc.).~13. A known allergy to any component of LY2157299.~14. Patients who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems include, but are not limited to:~    1. Other serious non-malignancy-associated medical conditions that may be expected to limit life expectancy or significantly increase the risk of Serious Adverse Events (SAEs).~   2. Any condition, psychiatric, substance abuse, or otherwise, that, in the opinion of the Investigator, would preclude informed consent, consistent follow-up, or compliance with any aspect of the study~15. Pregnant or nursing women, due to the unknown effects ofLY2157299 on the developing fetus or newborn infant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 - Study Drug & Radiation therapy (Type: EXPERIMENTAL): Study Drug: Enrolled patients will receive 300 mg/day of LY2157299. LY2157299 will be administered as an oral drug tablet.~The study drug will be administered orally on a 28-day cycle (1 cycle=28 days), every 2 weeks, or 14 days on / 14 days off. Blood samples will be obtained at baseline, and weeks 2, 6 and 15 for immune monitoring.~Radiation therapy : Patients will receive Radiation therapy to a metastatic site at a dose of 7.5 Gy, given consecutively on days 1, 3 and 5, during Week 1 of their treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues